Patient-derived Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: A Phase I Study
Research Grant Recipient: LaTonya Hickson, MD
Award Value: $500,000
Research Focus: Diabetes-related kidney failure
From the investigator:
Diabetic kidney disease (DKD) is the most common cause of kidney failure in the U.S. and has no adequate cure. Mesenchymal stromal cell (MSC) transplantation is an exciting new treatment, with a potential to slow the progression of kidney failure. Our goal is to assess the safety, tolerability, feasibility and early efficacy signals that relate to response to intra-arterial kidney delivery of autologous adipose tissue-derived MSCs in patients with DKD. The proposed studies in Minnesotans will lay the foundation for development of a therapy that may dramatically affect millions of patients across the U.S. by distinctly altering the trajectory of DKD.